Nahon Pierre, Vibert Eric, Nault Jean-Charles, Ganne-Carrié Nathalie, Ziol Marianne, Seror Olivier
Service d'Hépatologie, AP-HP, Hôpital Jean Verdier, Bondy, France.
"Equipe labellisée Ligue Contre le Cancer", Université Paris 13, Sorbonne Paris Cité, Saint-Denis, France.
Liver Int. 2020 Feb;40 Suppl 1:109-115. doi: 10.1111/liv.14345.
The goal of curative management of hepatocellular carcinoma is to provide the best chance of remission. However, recurrence rates for both local and distant relapse are high. Patient subgroups at higher risk of these events can be identified based on histological patterns that are closely linked to specific molecular subtypes. Patient outcome has improved with more effective therapeutic strategies thanks to technological advances in surgical techniques and percutaneous ablation. The main goal of controlling the cause of liver disease is to decrease distant/late recurrence and prevent deterioration of hepatic function. Ongoing trials testing the combination of neoadjuvant and/or adjuvant regimens with these procedures as well as routine tumour molecular analysis may modify therapeutic algorithms for hepatocellular carcinoma in the future.
肝细胞癌根治性治疗的目标是提供最佳的缓解机会。然而，局部和远处复发的发生率都很高。基于与特定分子亚型密切相关的组织学模式，可以识别出发生这些事件风险较高的患者亚组。由于手术技术和经皮消融技术的进步，更有效的治疗策略使患者的预后得到了改善。控制肝脏疾病病因的主要目标是减少远处/晚期复发并防止肝功能恶化。正在进行的试验测试新辅助和/或辅助治疗方案与这些手术的联合应用以及常规肿瘤分子分析，可能会在未来改变肝细胞癌的治疗算法。
